BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

IVI inks MoU with the Nepal Health Research Council

March 15, 2021 | News

To build research and development capacity in Nepal and jointly pursue opportunities to improve public health in the region



The International Vaccine Institute (IVI) in South Korea and the Nepal Health Research Council (NHRC) have signed a Memorandum of Understanding (MoU) today during a virtual ceremony, laying the foundation for the two organizations to build research and development capacity in Nepal and jointly pursue opportunities to improve public health in the region.

“IVI welcomes this new partnership agreement with NHRC to promote and build capacity for vaccine research and education. IVI and the government of Nepal, a signatory of IVI, have benefited from a long-standing research partnership including vaccine delivery campaigns, and we look forward to more opportunities with the NHRC to build sustainable solutions to Nepal’s public health problems,” said George Bickerstaff, Chairperson of IVI’s Board of Trustees.

“With this MOU, we will establish a synergistic health research collaboration to promote research and innovation for health in a range of clinical and public health research of mutual interests. This international scientific partnership shall foster transformation in health research in region through networking, technology transfer, dovetailing expertise and scientific information, and others.” said Dr. Pradip Gyanwali, Executive Chief of NHRC.

With this MOU, collaborative efforts may include Good Clinical Practice and Good Clinical Laboratory Practice trainings at medical schools and hospitals, and vaccinology courses to train young scientists, healthcare workers, and researchers.

IVI’s ongoing and past efforts with universities, research organizations and health facilities in Nepal include significant capacity building in terms of infrastructure and trainings, quality execution of a Phase III clinical trial of a new typhoid conjugate vaccine which met its primary endpoints at the end of 2020, typhoid vaccination campaigns and subsequent impact studies, data collection for national antimicrobial resistance, as well as vaccination campaigns to protect Nepalese populations from cholera.

Image caption- George Bickerstaff, IVI's Board Chairperson (top), IVI (bottom left) and the NHRC (bottom right) sign an MoU to pursue collaborative vaccine research